Highlights Entrada Therapeutics, Inc.

Equities

TRDA

US29384C1080

Real-time Estimate Cboe BZX Other stock markets 11:03:05 2024-05-22 am EDT			5-day change	1st Jan Change
16.1 ^USD	+2.55%		+11.28%	+6.86%

May. 20	Entrada Therapeutics Insider Sold Shares Worth $287,695, According to a Recent SEC Filing	MT
May. 16	Entrada Therapeutics Insider Bought Shares Worth $364,673, According to a Recent SEC Filing	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Entrada Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07	CI
Entrada Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 13	CI
Entrada Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 13	CI
North American Morning Briefing : Stock Futures -2-	Mar. 11	DJ
Entrada Therapeutics Says FDA Declined to Lift Clinical Hold on Application for Phase 1 Duchenne Muscular Dystrophy Trial	Nov. 22	MT
Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy	Nov. 22	CI
Entrada Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Entrada Therapeutics, Inc. Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy	23-09-21	CI
Entrada Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08	CI
Entrada Therapeutics Gets UK Nod To Initiate Duchenne Muscular Dystrophy Trial	23-08-01	MT
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate Phase 1 Clinical Trial of Entr-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy	23-08-01	CI
Entrada Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
ENTRADA THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	23-03-06	AQ
Entrada Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-06	CI
Entrada Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-03-06	CI
Entrada Therapeutics, Inc. Closes Agreement with Vertex to Discover and Develop Endosomal Escape Vehicle-Therapeutics for Myotonic Dystrophy Type 1	23-02-09	CI
Entrada Therapeutics, Inc. Announces Clinical Candidate, ENTR-601-45, for the Potential Treatment of People Living with Duchenne Muscular Dystrophy who are Exon 45 Skipping Amenable	23-01-09	CI
North American Morning Briefing : Futures Waver After BoJ Policy Shift	22-12-20	DJ
Entrada Therapeutics, Inc. Announces Clinical Hold on IND Application for ENTR-601-44 in Duchenne Muscular Dystrophy	22-12-19	CI
Vertex, Entrada Sign Deal to Develop Endosomal Escape Vehicle Therapeutics	22-12-08	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Entrada Therapeutics, Inc.

Equities

TRDA

US29384C1080

Highlights

Filters